Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
eNrFmN9v2jAQx9/5K6K8EyfQFpgC1cbaDWnVGC3atBdkkqM4C3bqH0D3188hdKOTo66mXp8QsXN3ufv6c5fE59tV7q2BC8Jo34+C0PeAJiwl9LbvT28um13/fNCIM7zGB9v0vqDV8r0kx0L0/XI1mAOmIvh29ek96PuB+4OGF7N5Bol8tE9JkgcfsVhe4aLc48VrRlJvBXLJ0r5fKLm76sVCch3FYMP4D1HgBGK0v3K4ms1ODq/HqDT2D1aVAP4J01uj0QW3spkozoHKIZZwy/i92XQyi1qnYdjtWbkgYgKCKZ7AGMvlmLM1SSE1e8K5ACsni016DXydgyydGI2jLFkJK+M4w9sJ3I3MQb/Vq0O5lc2wGXWi0/Ck19bp6kVWrvhBqszi0Q+Bilk77Jx1eh204CiFhJQab9JWGPWaYdQ+Q2mCMoFyMkcrttL13f8EmbAs4ZhxiXNHxSNi+FiGjvxwuHtSJCkRRY7vdaYK21RhjvUycA0Ldw9SPsEN1/jKdc7+sk9VnqNnRj3dw8VRxCW7hkxRWcOYy4ltIoaMStjWV9QOi3K71yIB8XJmfzJqbgljNc9JYks+zSYFQk4no3rwvQIz3mEBU+4OGl8JTdlGvDyMDovvKPpix9O6dtvqdk57Hfsp4bvWWU23ulCcFYA0pIg4hj0jumDHUkdL12zqQbj/W7O7CYslOIeaGWtmySkt1oeR0NlxcHfUqgWj0Q8XN7Yq+qKA31/v/hpNk7T/u/52EHfRGbRmawN//gmoMPDU9K1xcNJtd+0kzc2UWUpZiDcIbTabYIlFU2CdrEAfs1dqFgdt3N0rgpNZoZqdKuQ6Cn1eddLnFdL2XD41TRw7Ie/v30/iRh+SKziiFhXCnYF2dPHy7P4zHjsLe/yINe7c7EZZLDUwXM1Oam60eFy30HWll1wD4vNiQWq+3NTqMkbVV6NBI0blF6NB4xcXLhrd
pb9MEqYYSapYBRmN